I-Mab reports efficacy of Anti-CD47 monoclonal Ab on relapsed/refractory malignancy

Clinical Trial Phase |  Company results | 0 Comment | 25 Nov, 2020

I-Mab, a global clinical-stage biopharmaceutical company based in China and the US and committed to the discovery, devel...Read more

Gilead’s Biktarvy sustains viral suppression and tolerability in Asian HIV patients

Clinical Trial Phase |  News | 0 Comment | 16 Oct, 2020

Gilead Sciences, Inc. on 15 Oct 2020 announced findings from multiple studies in Asian population that evaluated th...Read more